Graphic Packaging Holding Company Announces Receipt of All Required Regulatory Approvals for Pending Acquisition with AR Packaging

Q2 2020 Highlights *Sales of $1,285 million (compared with $1,313 million in Q1 2020 (-2%) and $1,275 million in Q2 2019 (+1%)) As reported (including specific items) *Operating income of $94 million (compared with of $90 million in Q1 2020 (+4%) and an operating income of $82 million in Q2 2019 (+15%)) *Net earnings per share of $0.57 (compared with $0.24 in Q1 2020 and $0.33 in Q2 2019)

International Paper is pleased to announce that it received the necessary shareholder approval for its pending acquisition of DS Smith. Earlier this week, DS Smith also received the necessary shareholder approval for the Combination. International Paper will report the final vote results of the special shareholder meeting in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the "SEC"). International Paper and DS Smith continue to expect the Combination to close late in the fourth quarter of 2024, subject to regulatory clearance and other customary closing conditions. "The overwhelming approval from both DS Smith and IP shareholders confirms the strong support of this combination," said Andy Silvernail, Chairman and CEO of International Paper. "Bringing the two companies together will create a true global leader of sustainable packaging solutions which will drive significant value for our employees, customers and shareholders."

AptarGroup, Inc. announced that it has entered into exclusive negotiations with respect to a potential acquisition of all outstanding shares of Voluntis (ENXTPA: ALVTX), a pioneer in digital therapeutics. This acquisition would complement Aptar’s existing digital health portfolio of connected devices by adding digital therapeutic solutions and broadening its digital health services across multiple chronic conditions and diseases. Digital therapeutics (DTx) help patients and caregivers treat, manage, or prevent a disorder or disease through evidence-based interventions that are driven by high quality software solutions. Supported by the trend toward personalized healthcare, DTx are used independently or in connection with medications, devices or other therapies to optimize patient care and health outcomes. By acquiring Voluntis, Aptar would have immediate access to an established proprietary platform and algorithms that would drive future digital solutions provided to pharmaceutical and biotech customers as well as other healthcare stakeholders including payers and providers.